Page last updated: 2024-12-05

phloretin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Phloretin is a dihydrochalcone found in apples, pears, and other fruits. It is a potent antioxidant with potential health benefits. Phloretin has been shown to have anti-inflammatory, anti-diabetic, and anti-cancer effects in various studies. It is also known to inhibit the activity of certain enzymes, including tyrosinase, which is involved in melanin production. Researchers are studying phloretin for its potential to prevent and treat various diseases, including Alzheimer's disease, Parkinson's disease, and cardiovascular disease. The compound can be synthesized using various chemical methods, but it is also commercially available.'

Cross-References

ID SourceID
PubMed CID4788
CHEMBL ID45068
CHEBI ID17276
SCHEMBL ID38131
MeSH IDM0016612

Synonyms (138)

Synonym
BIDD:ER0174
BRD-K15563106-001-02-4
CHEBI:17276 ,
3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one
KBIO1_001373
DIVK1C_006429
SDCCGMLS-0066637.P001
G50 ,
EU-0101012
3-(4-hydroxy-phenyl)-1-(2,4,6-trihydroxy-phenyl)-propan-1-one
phloretin, >=99%
SPECTRUM_001295
SMP1_000238
tnp00255
NCGC00015840-02
NCGC00015840-01
lopac-p-7912
LOPAC0_001012
BSPBIO_002851
BCBCMAP01_000040
SPECTRUM5_001698
OPREA1_824722
phloretol
propiophenone,4',6'-trihydroxy-3-(p-hydroxyphenyl)-
dihydronaringenin
.beta.-(p-hydroxyphenyl)phloropropiophenone
.beta.-(p-hydroxyphenyl)-2,6-trihydroxypropiophenone
2',6'-trihydroxy-3-(p-hydroxyphenyl)propiophenone
NSC407292 ,
nsc-407292
beta-(4-hydroxyphenyl)-2,4,6-trihydroxypropiophenone
2',4',6'-trihydroxy-3-(4-hydroxyphenyl)propiophenone
beta-(p-hydroxyphenyl)-2,4,6-trihydroxypropiophenone
2',4',6'-trihydroxy-3-(p-hydroxyphenyl)propiophenone
1-propanone, 3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-
propiophenone, 2',4',6'-trihydroxy-3-(p-hydroxyphenyl)-
3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-1-propanone
beta-(p-hydroxyphenyl)phloropropiophenone
phloretin ,
C00774
60-82-2
MLS000728507
smr000326783
MLS000859922
NCGC00094304-02
NCGC00094304-03
c15h14o5
KBIO3_002071
KBIO2_006911
KBIOSS_001775
KBIOGR_001803
KBIO2_004343
KBIO2_001775
SPECTRUM2_000681
SPECTRUM3_001036
SPBIO_000801
SPECTRUM4_001172
SPECPLUS_000333
SPECTRUM300554
ccris 7459
NCGC00094304-04
cid_4788
chembl45068 ,
nsc 407292
bdbm23446
NCGC00094304-01
einecs 200-488-7
inchi=1/c15h14o5/c16-10-4-1-9(2-5-10)3-6-12(18)15-13(19)7-11(17)8-14(15)20/h1-2,4-5,7-8,16-17,19-20h,3,6h
LMPK12120525
NCGC00015840-03
P 7912
NCGC00015840-08
2',4,4',6'-tetrahydroxy-dihydrochalcone
DB07810
2',4,4',6'-tetrahydroxydihydrochalcone
HMS3263K05
P1966
cas-60-82-2
dtxcid702393
tox21_202854
NCGC00260400-01
dtxsid6022393 ,
HMS2224N17
CCG-38573
NCGC00015840-07
NCGC00015840-05
NCGC00015840-06
NCGC00015840-04
s5j5oe47mk ,
4,2',4',6'-tetrahydroxydihydrochalcone
unii-s5j5oe47mk
FT-0603256
STL372996
NCGC00015840-09
LP01012
3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-propan-1-one [fhfi]
phloretin [inci]
fema no. 4390
phloretin [mi]
AKOS015856338
S2342
gtpl4285
HMS3332J03
CS-1477
HY-N0142
MLS006012024
REGID_FOR_CID_4788
SCHEMBL38131
2UXI
tox21_501012
NCGC00261697-01
SY017103
mfcd00002288
1-(2,4,6-trihydroxyphenyl)-3-(4-hydroxyphenyl)-1-propanone
.beta.-(p-hydroxyphenyl)-2,4,6-trihydroxypropiophenone
Q-100701
HB0500
3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-1-propanon
phloretin, analytical reference material
rjc 02792
2',4',6'-trihydroxy-3-(4-hydroxyphenyl)-propiophenone
AC-7995
HMS3656I07
asebogenol
SR-01000076081-8
sr-01000076081
SR-01000076081-1
SR-01000076081-7
SW219308-1
bp_35
phloretin - cas 60-82-2
Q2268463
AS-14100
BCP28296
BRD-K15563106-001-10-7
SDCCGSBI-0050985.P003
NCGC00015840-18
nsc 407292;rjc 02792

Research Excerpts

Overview

Phloretin (PLT) is a phenolic compound reported possessing anti-inflammatory and antioxidant activities. It is a natural dihydrochalcone found in many fruits and vegetables, especially in apple tree leaves and the Manchurian apricots.

ExcerptReferenceRelevance
"Phloretin is a powerful antioxidant with many effects, such as anti-cancer, anti-inflammatory, promoting cell renewal, delaying aging and so on. "( Nanostructured lipid carriers for the encapsulation of phloretin: preparation and in vitro characterization studies.
Gu, L; Sun, R; Wang, W; Xia, Q, 2022
)
2.41
"Phloretin is a dihydrochalcone flavonoid from natural plants, which has protective activities against oxidative stress and inflammation. "( Phloretin ameliorates diabetic nephropathy by inhibiting nephrin and podocin reduction through a non-hypoglycemic effect.
Cui, X; Jiang, J; Liu, J; Sun, M; Xia, Y, 2022
)
3.61
"Phloretin is a type of dihydrochalcone that is primarily found in apples and has been reported to possess various potent biological activities, such as anticancer, antioxidant and anti-inflammatory effects. "( Phloretin enhances autophagy by impairing AKT activation and inducing JNK-Beclin-1 pathway activation.
Fan, C; Teng, J; Tian, Y; Zhang, Y; Zhao, X, 2022
)
3.61
"Phloretin is a flavonoid of the dihydrogen chalcone class, present abundantly in apples and strawberries. "( Therapeutic Potential and Pharmaceutical Development of a Multitargeted Flavonoid Phloretin.
Agrawal, YO; Badwaik, H; Choudhary, R; Goyal, SN; Nakhate, KT; Ojha, S; Sakure, K; Sharma, C, 2022
)
2.39
"Phloretin (PLT) is a phenolic compound reported possessing anti-inflammatory and antioxidant activities."( Neuroprotective Effect of Phloretin in Rotenone-Induced Mice Model of Parkinson's Disease: Modulating mTOR-NRF2-p62 Mediated Autophagy-Oxidative Stress Crosstalk.
Khatri, DK; Kumar, R; Preeti, K; Shirgadwar, SM; Singh, SB, 2023
)
1.93
"Phloretin is a natural dihydrochalcone found in many fruits and vegetables, especially in apple tree leaves and the Manchurian apricots, exhibiting several therapeutic properties, such as antioxidant, antidiabetic, anti-inflammatory, and antitumor activities. "( Phloretin, as a Potent Anticancer Compound: From Chemistry to Cellular Interactions.
Chauhan, A; Haque, S; Jaswal, VS; Ramniwas, S; Rath, P; Sak, K; Tuli, HS; Varol, M; Vashishth, K, 2022
)
3.61
"Phloretin (PHL) is a dihydrochalcone flavonoid isolated from the peel and root bark of apples, strawberries, and other plants with antioxidative characteristic. "( Protective Effect of Phloretin against Hydrogen Peroxide-Induced Oxidative Damage by Enhancing Autophagic Flux in DF-1 Cells.
Bi, H; Li, X; Liu, F; Shu, J; Song, D; Tao, W; Wang, D; Wu, X, 2022
)
2.48
"Phloretin is a dihydrochalcone natural product, with its mono-C-glucoside, nothofagin, having various health-promoting effects."( Sequence mining yields 18 phloretin C-glycosyltransferases from plants for the efficient biocatalytic synthesis of nothofagin and phloretin-di-C-glycoside.
Gala, VD; Putkaradze, N; Teze, D; Vaitkus, D; Welner, DH, 2023
)
1.93
"Phloretin is a dihydrochalcone present in apple, pear and strawberries."( Phloretin suppresses intestinal inflammation and maintained epithelial tight junction integrity by modulating cytokines secretion in in vitro model of gut inflammation.
Kapoor, S; Padwad, YS,
)
2.3
"Phloretin (Ph) is a natural phenolic compound, that exhibits a wide array of pharmacological actions including its efficacy towards NAFLD."( Amorphous solid dispersion augments the bioavailability of phloretin and its therapeutic efficacy via targeting mTOR/SREBP-1c axis in NAFLD mice.
Anand, P; Chhimwal, J; Dhritlahre, RK; Padwad, YS; Patial, V; Saneja, A, 2023
)
1.87
"Phloretin is an important skin-lightening and depigmenting agent from the peel of apples. "( Raising the production of phloretin by alleviation of by-product of chalcone synthase in the engineered yeast.
Cai, Y; Chen, X; Jiang, C; Jiang, H; Liu, T; Liu, X; Liu, Y; Wang, H; Wang, W; Zhu, X; Zhuang, Y, 2020
)
2.3
"Phloretin is a promising polyphenolic compound known for its anti-inflammatory properties, but its poor solubility and low bioavailability hinder its clinical applicability. "(
Abu-Azzam, O; Nasr, M, 2020
)
2
"Phloretin is a natural dihydrochalcone flavonoid that is mainly distributed in apple, pear and other juicy fruit peels or root peels. "( Studies on pharmacokinetic properties and absorption mechanism of phloretin: In vivo and in vitro.
Cheng, JX; Fan, Y; Guo, DY; Shi, YJ; Wang, J; Wang, M; Zhang, XF; Zhao, YY; Zou, JB, 2020
)
2.24
"Phloretin is a naturally occurring dietary flavonoid that is abundant in fruit."( Phloretin as a Potent Natural TLR2/1 Inhibitor Suppresses TLR2-Induced Inflammation.
Durai, P; Jeon, D; Jung, ID; Kim, J; Kim, Y; Lee, SJ; Park, YM, 2018
)
2.64
"Phloretin (Phl) is a dihydrochalcone flavonoid with significant cytoprotective properties; e.g., free radical trapping, electrophile scavenging. "( Phloretin cytoprotection and toxicity.
Geohagen, BC; Korsharskyy, B; LoPachin, RM; Nordstroem, L; Vydyanatha, A, 2018
)
3.37
"Phloretin is a flavonoid with known anticancer activities. "( Phloretin Inhibits the Human Prostate Cancer Cells Through the Generation of Reactive Oxygen Species.
Kim, CY; Kim, J; Kim, U; Lee, JM; Oh, H; Park, JH; Ryu, B, 2020
)
3.44
"Phloretin is a natural chalcone with antibacterial and anti-inflammatory effects. "( Target Proteins of Phloretin for Its Anti-Inflammatory and Antibacterial Activities Against
Cheon, D; Jeon, D; Kim, J; Kim, Y; Shin, HC, 2019
)
2.29
"Phloretin is a known modifier of the internal dipole potential of lipid membranes. "( Effect of phloretin on the binding of 1-anilino-8-naphtalene sulfonate (ANS) to 1,2-Dimyristoyl-sn-glycero-3-phosphocoline (DMPC) vesicles in the gel and liquid-crystalline state.
Cutró, AC; Montich, G; Roveri, OA, 2015
)
2.26
"Phloretin is a plant-derived phytochemical that is mainly present in apples."( The flavonoid phloretin suppresses stimulated expression of endothelial adhesion molecules and reduces activation of human platelets.
Baumann, G; Grimbo, N; Guether, C; Lorenz, M; Ludwig, A; Martus, P; Sanad, W; Stangl, K; Stangl, V; Ziemer, S, 2005
)
1.41
"Phloretin is an inhibitor of anion exchange and glucose and urea transport in human red cells. "( Interaction of phloretin with the anion transport protein of the red blood cell membrane.
Dix, JA; Forman, SA; Solomon, AK; Verkman, AS, 1982
)
2.06
"Phloretin is a flavonoid found exclusively in apples and in apple-derived products where it is present as the glucosidic form, namely, phloridzin (phloretin 2'-O-glucose). "( Bioavailability of phloretin and phloridzin in rats.
Aprikian, O; Besson, C; Crespy, V; Demigné, C; Manach, C; Morand, C; Rémésy, C, 2001
)
2.08
"Phloretin is a dihydrochalcone flavonoid that displays a potent antioxidant activity in peroxynitrite scavenging and the inhibition of lipid peroxidation. "( The antioxidant activity of phloretin: the disclosure of a new antioxidant pharmacophore in flavonoids.
Bast, A; Haenen, GR; Rezk, BM; van der Vijgh, WJ, 2002
)
2.05
"Phloretin is an inhibitor of the mammalian glucose transporter and the iodothyronine-5'-deiodinase. "( Phloretin inhibits cellular uptake and nuclear receptor binding of triiodothyronine in human hep G2 hepatocarcinoma cells.
Movius, EG; Phyillaier, MM; Robbins, J, 1989
)
3.16

Effects

Phloretin has been shown to inhibit elastase and matrix metalloproteinase-1 activity, to reduce cellular tyrosinase activity and melanin content, and induce apoptosis in B16 mouse melanoma 4A5 cells. It has pleiotropic effects, including glucose transporter (GLUT) inhibition.

ExcerptReferenceRelevance
"Phloretin has been shown to inhibit elastase and matrix metalloproteinase-1 activity, to reduce cellular tyrosinase activity and melanin content, and induce apoptosis in B16 mouse melanoma 4A5 cells."( Dermatological applications of the flavonoid phloretin.
Anunciato Casarini, TP; Frank, LA; Guterres, SS; Pohlmann, AR, 2020
)
1.54
"Phloretin has been proven to have many biological activities such as anti-inflammatory and anti-oxidative."( The protective role of phloretin against dextran sulfate sodium-induced ulcerative colitis in mice.
Cao, H; Cao, Y; Fu, Y; Li, S; Liu, J; Shen, P; Zhang, N; Zhang, Z, 2019
)
1.55
"Phloretin has pleiotropic effects, including glucose transporter (GLUT) inhibition. "( Phloretin Suppresses Bone Morphogenetic Protein-2-Induced Osteoblastogenesis and Mineralization via Inhibition of Phosphatidylinositol 3-kinases/Akt Pathway.
Kanazawa, I; Notsu, M; Sugimoto, T; Takeno, A; Tanaka, KI, 2019
)
3.4
"Phloretin has no effect on the slow 4-aminopyridine-resistant K channels."( Phloretin affects the fast potassium channels in frog nerve fibres.
Klusemann, J; Meves, H, 1991
)
2.45

Actions

Phloretin does not increase the level of Bax protein. It does not inhibit [3H]AEA efflux from cells. It can enhance the killing effect of γδ T cells on SW-1116 cells.

ExcerptReferenceRelevance
"Phloretin could also cause the arrest of the AGS gastric cancer cells in the G2/M phase of the cell cycle and suppress their ability to migrate."( Anticancer Activity of Phloretin Against Human Gastric Cancer Cell Lines Involves Apoptosis, Cell Cycle Arrest, and Inhibition of Cell Invasion and JNK Signalling Pathway.
Gu, W; Shen, Z; Wang, F; Xu, M, 2018
)
1.51
"Phloretin could inhibit the absorption of glucose significantly. "( [Effects of ginsenoside Re on glucose absorption in Caco-2 cells].
Chen, WW; Guo, WF; Liu, J; Ren, L, 2013
)
1.83
"Phloretin can inhibit BEL-7402 cells' malignant pheotype."( [Study on the effect of phloretin on inhibiting malignant pheotype of BEL-7402 cells].
Chen, J; Liu, JQ; Luo, H; Wang, YJ, 2008
)
2.1
"Phloretin did not cause changes in the dipole potential of dimyristoylphosphatidylethanolamine (DMPE), and in consequence, no effects on the zeta potential were measured."( Effect of dipole potential variations on the surface charge potential of lipid membranes.
Disalvo, EA; Lairion, F, 2009
)
1.07
"Phloretin can enhance the killing effect of γδ T cells on SW-1116 cells; the mechanism may be that Phloretin could proliferate the γδ T cell growth, increase the expression of PFP and GraB, activate the Wnt signaling pathway, and produce higher level of IFN-γ. "( The effect of phloretin on human γδ T cells killing colon cancer SW-1116 cells.
Chen, FX; Fei, SJ; Liu, G; Liu, JQ; Wu, XT; Zhang, JF; Zhou, ZH; Zhu, SP, 2013
)
2.19
"The phloretin-induced increase in intracellular Ca(2+) was unaffected by the removal of extracellular Ca(2+) and co-application of paxilline."( BK channel openers inhibit migration of human glioma cells.
Basrai, D; Bolz, J; Jung, S; Kraft, R; Krause, P; Liebmann, L; Patt, S, 2003
)
0.8
"Phloretin does not inhibit Na+ transport independent of glucose transport in H."( Phloretin inhibition of glucose transport by the tapeworm Hymenolepis diminuta: a kinetic analysis.
Lumsden, RD; Murphy, WA, 1984
)
2.43
"Phloretin was found to inhibit neutrophil degranulation, aggregation and calcium uptake stimulated by the chemotactic peptide fMet-Leu-Phe."( Phloretin is a potent inhibitor of rabbit neutrophil activation by chemotactic factors.
Molski, TF; Naccache, PH; Sha'afi, RI; Shefcyk, J; Volpi, M, 1983
)
2.43
"Phloretin was shown to inhibit by around 80% the glycerol fluxes of wild and mutant hAQP1, hAQP2 and to fully inhibit glycerol uptake in GlpF-injected oocytes."( Glycerol permeability of mutant aquaporin 1 and other AQP-MIP proteins: inhibition studies.
Abrami, L; Berthonaud, V; Deen, PM; Ripoche, P; Rousselet, G; Tacnet, F, 1996
)
1.02
"Phloretin does not inhibit [3H]AEA efflux from cells."( Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion.
Campbell, WB; Edgemond, WS; Hillard, CJ; Jarrahian, A, 1997
)
1.02
"Phloretin did not increase the level of Bax protein."( Phloretin-induced apoptosis in B16 melanoma 4A5 cells and HL60 human leukemia cells.
Iwashita, K; Kobori, M; Shinmoto, H; Tsushida, T, 1999
)
2.47
"Like phloretin they inhibit the non-Na+-dependent, facilitated diffusion transport system for sugars associated with the lateral serosal boundary of intestinal epithelial cells."( Phloretin-like action of bioflavonoids on sugar accumulation capability of isolated intestinal cells.
Kimmich, GA; Randles, J, 1978
)
2.16
"(Phloretin may also increase the fluidity of cholesterol-containing membranes; this is manifested by its two- to three-fold increase in nonelectrolyte permeability and its asymmetrical effect on cation and anion conductances in cholesterol-containing membranes.) It is possible that pholoretin's inhibition of chloride, urea, and glucose transport in biological membranes results from the effects of these intense intrafacial dipole fields on the translocator(s) of these molecules."( Effect of phloretin on the permeability of thin lipid membranes.
Andersen, OS; Cass, A; Finkelstein, A; Katz, I, 1976
)
1.28

Treatment

The phloretin treatment retarded RANKL-induced expression of carbonic anhydrase II, vacuolar-type H(+) -ATPase D2 and β3 integrin, all involved in the bone resorption. The treatment significantly blocks high-fat diet-induced weight gain but did not induce weight loss in obese animals.

ExcerptReferenceRelevance
"Phloretin pretreatment reduced the LPS-induced release of IL-6 and IL-8 as well as VEGF."( Phloretin inhibits glucose transport and reduces inflammation in human retinal pigment epithelial cells.
Bhattarai, N; Hytti, M; Kanerva, I; Kauppinen, A; Nielsen, CU; Pedersen, ML; Ruuth, J, 2023
)
3.07
"Phloretin treatment significantly restrained cell viability and metastasis, induced DNA injury and ROS accumulation, and triggered mitochondrial-dependent apoptosis in PCCs. "( Phloretin-induced STAT3 inhibition suppresses pancreatic cancer growth and progression via enhancing Nrf2 activity.
Bai, Y; Deng, J; Huang, G; Jin, G; Li, G; Ruan, Q; Wen, C; Wen, Z; Yang, X; Yuan, Z, 2023
)
3.8
"Phloretin pretreatment dramatically suppressed the mucins secretion, inflammatory cell infiltration and inflammatory cytokine release in mouse lungs induced by CS, and it also suppressed CSE-induced expression of MUC5AC and IL-1β in NCI-H292 bronchial epithelial cells. "( Phloretin attenuates mucus hypersecretion and airway inflammation induced by cigarette smoke.
Chen, L; Hao, N; Shen, Y; Wang, H; Wang, T; Wen, F; Wu, Y; Yang, T; Yuan, Z, 2018
)
3.37
"Phloretin pretreatment significantly protected the presynaptic protein synaptophysin against the effects of Aβ1-42."( The effect of phloretin on synaptic proteins and adult hippocampal neurogenesis in Aβ (1-42)-injected male Wistar rats.
Francis, P; Ghumatkar, P; Howlett, D; Muke, S; Patil, S; Peshattiwar, V; Sathaye, S; Whitfield, D, 2018
)
1.56
"Phloretin treatment significantly attenuated the inflammatory response in macrophage cells (J774) co-cultured with S."( Phloretin reduces cell injury and inflammation mediated by Staphylococcus aureus via targeting sortase B and the molecular mechanism.
Gao, Y; Niu, X; Wang, G; Wang, H; Wang, J, 2018
)
2.64
"Phloretin (100 μM) treatment significantly inhibited the aldehyde dehydrogenase 1 activity of SiHa cells, reduced the self-renewal properties and stemness signatures of CD44 and Sox-2 in sphere-forming cervical cancer-derived tumor-initiating cells, and inhibited the invasion, MMP-2 activity, and tube formation capacity of human umbilical vein endothelial cells."( Phloretin suppresses metastasis by targeting protease and inhibits cancer stemness and angiogenesis in human cervical cancer cells.
Chen, PN; Chen, SP; Hsiao, YH; Hsieh, MJ; Tsai, WC; Yang, SF, 2019
)
2.68
"Phloretin treatment decreased the production of IL-6, IL-8, CCL5, MDC, and TARC."( Phloretin ameliorates chemokines and ICAM-1 expression via blocking of the NF-κB pathway in the TNF-α-induced HaCaT human keratinocytes.
Dai, YW; Huang, WC; Kang, CW; Kuo, CY; Liou, CJ; Peng, HL, 2015
)
2.58
"Phloretin treatment significantly blocks high-fat diet-induced weight gain but did not induce weight loss in obese animals."( Phloretin Prevents High-Fat Diet-Induced Obesity and Improves Metabolic Homeostasis.
Alsanea, S; Gao, M; Liu, D, 2017
)
2.62
"The phloretin treatment retarded RANKL-induced expression of carbonic anhydrase II, vacuolar-type H(+) -ATPase D2 and β3 integrin, all involved in the bone resorption."( Novel antiosteoclastogenic activity of phloretin antagonizing RANKL-induced osteoclast differentiation of murine macrophages.
Gong, JH; Han, SY; Kang, MK; Kang, YH; Kim, JL; Park, SH, 2012
)
1.13
"Phloretin treatment resulted in total inhibition of the residual aminopyrine accumulation after rotenone treatment."( Role of glucose metabolism in acid formation by isolated gastric glands.
Hersey, SJ; Miller, M; Owirodu, A, 1982
)
0.99
"Phloretin pretreatment markedly decreased the biliary and urinary excretions of BGD and HBGD."( Involvement of active transport systems in the mobilization of cadmium by dithiocarbamates in vivo.
Funakoshi, T; Kamenosono, T; Kojima, S; Shimada, H, 2002
)
1.04
"Pretreatment with phloretin on the dorsal skin of mice inhibited TPA-induced COX-2 expression in a dose-dependent manner."( Phloretin inhibits phorbol ester-induced tumor promotion and expression of cyclooxygenase-2 in mouse skin: extracellular signal-regulated kinase and nuclear factor-κB as potential targets.
Kundu, JK; Shin, JW; Surh, YJ, 2012
)
2.15
"Pretreatment with phloretin, an inhibitor of protein kinase C, has no affect on the vasoconstriction caused by infusion of a KCl bolus, but it does inhibit in a dose-dependent manner the response to 12,13-phorbol and mezerein."( Protein kinase C-mediated pulmonary vasoconstriction in rabbit: role of Ca2+, AA metabolites, and vasodilators.
Farrukh, IS; Gurtner, GH; Michael, JR; Yang, J, 1993
)
0.61

Toxicity

ExcerptReferenceRelevance
" Neutral red uptake showed that ascorbate, but not dehydroascorbate, was highly toxic in the MMe cell lines REN and MM98, and less toxic in immortalized (human mesothelial cells-htert) and primary mesothelial cells."( Selective ascorbate toxicity in malignant mesothelioma: a redox Trojan mechanism.
Biffo, S; Burlando, B; Ranzato, E, 2011
)
0.37
" Thus, in spite of possessing cytoprotective attributes, Phl was generally toxic in our APAP models."( Phloretin cytoprotection and toxicity.
Geohagen, BC; Korsharskyy, B; LoPachin, RM; Nordstroem, L; Vydyanatha, A, 2018
)
1.92

Compound-Compound Interactions

ExcerptReferenceRelevance
"In this study, the effect of lipophilic counter-ions on the permeation of 5-aminolevulinic acid (ALA) in combination with skin impregnation by phloretin and 6-ketocholestanol was evaluated."( Influence of lipophilic counter-ions in combination with phloretin and 6-ketocholestanol on the skin permeation of 5-aminolevulinic acid.
Auner, BG; Hadgraft, J; Valenta, C, 2003
)
0.77
"In this study, off-line two-dimensional High Speed Counter-Current Chromatography (2D HSCCC) strategy combined with recycling elution mode was developed to isolate compounds from the ethyl acetate extract of a common green tea--leaves of Malus hupehensis (Pamp."( Separation of polyphenols from leaves of Malus hupehensis (Pamp.) Rehder by off-line two-dimensional High Speed Counter-Current Chromatography combined with recycling elution mode.
Chen, X; Jiang, S; Liu, Q; Yang, F; Yang, H; Zeng, H; Zhang, L, 2015
)
0.42

Bioavailability

Phloretin is a promising polyphenolic compound known for its anti-inflammatory properties. Its poor solubility and low bioavailability hinder its clinical applicability.

ExcerptReferenceRelevance
" During the steady state, the rate of absorption of 3MG from the intestinal lumen is equal to the rate of appearance in the portal venous effluent; this rate of transfer is to a small, but significant, extent directly related to the rate of arterial perfusion."( Effects of vascular perfusion on the accumulation, distribution and transfer of 3-O-methyl-D-glucose within and across the small intestine.
Boyd, CA; Parsons, DS, 1978
)
0.26
"Naringenin and its derivatives have been assessed in bone health for their oestrogen-'like' effects but low bioavailability impedes clinical potential."( A naturally occurring naringenin derivative exerts potent bone anabolic effects by mimicking oestrogen action on osteoblasts.
Chattopadhyay, N; Dwivedi, AK; Gupta, V; Khan, K; Khan, MP; Maurya, R; Mishra, JS; Rawat, P; Sanyal, S; Sharan, K; Siddiqui, JA; Swarnkar, G, 2012
)
0.38
" NCG had better oral bioavailability than naringenin."( A naturally occurring naringenin derivative exerts potent bone anabolic effects by mimicking oestrogen action on osteoblasts.
Chattopadhyay, N; Dwivedi, AK; Gupta, V; Khan, K; Khan, MP; Maurya, R; Mishra, JS; Rawat, P; Sanyal, S; Sharan, K; Siddiqui, JA; Swarnkar, G, 2012
)
0.38
" Furthermore, dietary sugars and flavonoids in fruits and vegetables may modulate Asc bioavailability via inhibition of small intestinal GLUT2 and GLUT8."( Intestinal dehydroascorbic acid (DHA) transport mediated by the facilitative sugar transporters, GLUT2 and GLUT8.
Al-Hasani, H; Corpe, CP; Eck, P; Levine, M; Wang, J, 2013
)
0.39
" While a few studies have been conducted to evaluate the bioavailability of anthocyanins, the mechanisms of their absorption mechanism remain ill-defined."( The role of sodium-dependent glucose transporter 1 and glucose transporter 2 in the absorption of cyanidin-3-o-β-glucoside in Caco-2 cells.
Feng, D; Li, HW; Ling, WH; Song, G; Tang, HW; Zou, TB, 2014
)
0.4
" Phloretin bioavailability is well known in humans, but still remains to be better studied in experimental animals, such as mouse and rat."( Phloretin-induced cytoprotective effects on mammalian cells: A mechanistic view and future directions.
de Oliveira, MR,
)
2.48
" The system recorded currents relative to glucose (1mM) absorption, obtaining bioavailability values (5."( Real-time monitoring of glucose and phenols intestinal absorption through an integrated Caco-2TC7cells/biosensors telemetric device: Hypoglycemic effect of fruit phytochemicals.
Barberis, A; Bazzu, G; Cardinali, A; D'Antuono, I; D'Hallewin, G; Fadda, A; Garbetta, A; Linsalata, V; Minervini, F; Rocchitta, G; Serra, PA, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Phloretin is a promising polyphenolic compound known for its anti-inflammatory properties, but its poor solubility and low bioavailability hinder its clinical applicability."(
Abu-Azzam, O; Nasr, M, 2020
)
2
" However, poor solubility and bioavailability of phloretin limits its clinical translation."( Amorphous solid dispersion augments the bioavailability of phloretin and its therapeutic efficacy via targeting mTOR/SREBP-1c axis in NAFLD mice.
Anand, P; Chhimwal, J; Dhritlahre, RK; Padwad, YS; Patial, V; Saneja, A, 2023
)
1.41

Dosage Studied

The addition of increasing concentrations of phloretin caused progressive shifts of the dose-response curves of PGF2 alpha to the right. A study revealed that the concentration of phLoretin causing half-maximal inhibition (K1/2) was 5 x 10(-4) M for adapted animals.

ExcerptRelevanceReference
" 3 These doses of DPP caused a marked shift to the left of the dose-response curve to prostaglandin E2 given intravenously but did not affect the dose-response curve to prostaglandin E2 given intra-arterially."( Inhibition of the pulmonary inactivation of prostaglandins in vivo by di-4-phloretin phosphate.
Crutchley, DJ; Piper, PJ, 1975
)
0.48
" A dose-response study revealed that the concentration of phloretin causing half-maximal inhibition (K1/2) was 5 x 10(-4) M for adapted animals."( Active urea transport by the skin of Bufo viridis: amiloride- and phloretin-sensitive transport sites.
Abuful, A; Chaimovitz, C; Hays, RM; Noeh, Z; Rapoport, J, 1988
)
0.76
" Dose-response studies of GS-Mal treatment of intact cells suggested that some functional carriers lack a reactive external sulfhydryl, which can be partially regenerated by pretreatment with excess cysteine."( Reaction of an exofacial sulfhydryl group on the erythrocyte hexose carrier with an impermeant maleimide. Relevance to the mechanism of hexose transport.
May, JM, 1988
)
0.27
" The addition of increasing concentrations of phloretin caused progressive shifts of the dose-response curves of PGF2 alpha to the right."( Phloretin as an antagonist of prostaglandin F2 alpha receptor in cultured rat astrocytes.
Baba, A; Ishibashi, T; Kitanaka, J, 1993
)
1.99
" The dose-response information for these metabolic regulators is crucial for designing future experiments."( Metabolic regulation of in-vitro-produced bovine embryos. I. Effects of metabolic regulators at different glucose concentrations with embryos produced by semen from different bulls.
De La Torre-Sanchez, JF; Preis, K; Seidel, GE, 2006
)
0.33
" After multiple dosing of developed NPs in mouse models with lung metastasis of melanoma, the CS-PLGA/Phl NPs group exhibited significantly lower lung weight and number of metastasis foci than the PLGA/Phl NPs group (p < 0."( Application of temporary agglomeration of chitosan-coated nanoparticles for the treatment of lung metastasis of melanoma.
Cho, HJ; Koo, JS; Lee, SY; Yang, M, 2019
)
0.51
" Mice were pretreated with low or high dosage of PHL for 7 days via intragastric administration once a day before LPS injection."( The inhibition of GLUT1-induced glycolysis in macrophage by phloretin participates in the protection during acute lung injury.
Li, W; Song, T; Songyang, Y; Yang, J, 2022
)
0.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dihydrochalconesAny ketone that is 1,3-diphenylpropanone and its derivatives obtained by substitution.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
flavonoid di-C-glucosylation022
phloridzin biosynthesis212
flavonoid di-C-glucosylation029

Protein Targets (104)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency22.38720.004023.8416100.0000AID485290
Chain A, HADH2 proteinHomo sapiens (human)Potency18.85410.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency18.85410.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency33.20580.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency12.58930.125919.1169125.8920AID2549
LuciferasePhotinus pyralis (common eastern firefly)Potency55.26860.007215.758889.3584AID1224835; AID588342
acetylcholinesteraseHomo sapiens (human)Potency57.67160.002541.796015,848.9004AID1347397
thioredoxin reductaseRattus norvegicus (Norway rat)Potency19.45590.100020.879379.4328AID488773; AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency32.98380.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency70.12700.006038.004119,952.5996AID1159521
ATAD5 protein, partialHomo sapiens (human)Potency2.90810.004110.890331.5287AID493107
USP1 protein, partialHomo sapiens (human)Potency77.03790.031637.5844354.8130AID504865; AID743255
GLS proteinHomo sapiens (human)Potency6.11930.35487.935539.8107AID624146; AID624170
TDP1 proteinHomo sapiens (human)Potency23.21150.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency67.53640.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency17.78280.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency39.92920.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
Smad3Homo sapiens (human)Potency5.62340.00527.809829.0929AID588855
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency33.99720.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency14.76240.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency7.44050.000657.913322,387.1992AID1259377; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency54.66520.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency31.32460.000417.946075.1148AID1346795
regulator of G-protein signaling 4Homo sapiens (human)Potency18.88760.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency1.80640.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency12.58930.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency7.07520.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency17.61510.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency23.03660.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency63.73530.001530.607315,848.9004AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency70.12700.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency27.33070.000229.305416,493.5996AID1259383; AID743069; AID743075; AID743077; AID743078; AID743079
glucocerebrosidaseHomo sapiens (human)Potency16.81590.01268.156944.6684AID2101
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency46.42170.001019.414170.9645AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency44.64160.023723.228263.5986AID743222
arylsulfatase AHomo sapiens (human)Potency2.68551.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.67020.035520.977089.1251AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency31.32460.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency50.08870.143427.612159.8106AID1159516
serine-protein kinase ATM isoform aHomo sapiens (human)Potency28.18380.707925.111941.2351AID485349
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency32.46480.00207.533739.8107AID891
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency31.38140.036619.637650.1187AID2100
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency31.62280.316212.443531.6228AID902
cytochrome P450 2C19 precursorHomo sapiens (human)Potency11.96690.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency7.55060.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency30.74100.001815.663839.8107AID894
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency44.66840.010039.53711,122.0200AID1469
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency12.58930.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency64.99380.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency56.20040.042027.378961.6448AID743210
DNA polymerase betaHomo sapiens (human)Potency48.10230.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency30.47650.039816.784239.8107AID1454; AID995
flap endonuclease 1Homo sapiens (human)Potency25.11890.133725.412989.1251AID588795
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency31.62280.010323.856763.0957AID2662
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency35.37990.000627.21521,122.0200AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency31.62280.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency0.29090.004611.374133.4983AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency35.48130.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency9.28140.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency0.70790.177824.735279.4328AID488949
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency31.62280.251215.843239.8107AID504327
lethal factor (plasmid)Bacillus anthracis str. A2012Potency7.94330.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency0.00500.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency9.28141.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency12.58930.316212.765731.6228AID881
Cellular tumor antigen p53Homo sapiens (human)Potency70.12700.002319.595674.0614AID651631; AID720552
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency9.28141.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency9.28141.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency9.28141.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency9.28141.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency9.28141.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency9.28141.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency9.28141.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency9.28141.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency9.28141.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency9.28141.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency9.56610.00638.235039.8107AID881; AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency9.28141.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency9.28141.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency9.28141.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency9.28141.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency9.28141.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Monocarboxylate transporter 4Homo sapiens (human)IC50 (µMol)41.00000.00100.36840.8600AID678792
Epidermal growth factor receptorHomo sapiens (human)IC50 (µMol)25,000.00000.00000.536910.0000AID378668
Pancreatic triacylglycerol lipaseSus scrofa (pig)IC50 (µMol)50.40000.00401.10246.5000AID1464929
Chymotrypsinogen ABos taurus (cattle)IC50 (µMol)496.00000.98004.05607.2000AID1510602
Estrogen receptorHomo sapiens (human)IC50 (µMol)0.30000.00000.723732.7000AID1058214
Beta-lactamaseEnterobacter cloacaeIC50 (µMol)496.00000.10001.87457.7000AID1510602
Solute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)IC50 (µMol)21.40000.00492.99549.9920AID1058218
Sodium/glucose cotransporter 1Homo sapiens (human)IC50 (µMol)12.40000.06071.61058.4440AID1436776
Sodium/glucose cotransporter 1Homo sapiens (human)Ki86.00000.18003.86007.5400AID205450
Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)IC50 (µMol)41.00000.00011.97318.0000AID1142307
Sodium/glucose cotransporter 2Homo sapiens (human)IC50 (µMol)18.30000.00050.16534.1000AID1436777
Monocarboxylate transporter 1Rattus norvegicus (Norway rat)IC50 (µMol)28.00000.28100.28100.2810AID681133
Nuclear factor NF-kappa-B p100 subunit Homo sapiens (human)IC50 (µMol)41.00000.00011.80888.0000AID1142307
Transcription factor p65Homo sapiens (human)IC50 (µMol)41.00000.00011.89818.8000AID1142307
Monocarboxylate transporter 2Rattus norvegicus (Norway rat)IC50 (µMol)14.00005.00007.00009.0000AID681123
Sodium/hydrogen exchanger 9B2Homo sapiens (human)IC50 (µMol)90.000090.000090.000090.0000AID1794821
Solute carrier family 28 member 3Homo sapiens (human)Ki32.28002.10002.75003.4000AID370698
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Hth-type Transcriptional Regulator TtgrPseudomonas putidaKd0.05000.05009.025018.0000AID977611
Chain A, Hth-type Transcriptional Regulator TtgrPseudomonas putidaKd0.05000.05009.025018.0000AID977611
serine/threonine-protein kinase 33 isoform aHomo sapiens (human)EC50 (µMol)21.41000.769114.609644.8900AID2821
TransthyretinHomo sapiens (human)Kd8.10000.00301.348210.0000AID1705465
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
fibroblast growth factor 22 isoform 1 precursorHomo sapiens (human)AbsAC0.54_uM2.95002.95002.95002.9500AID743019
fibroblast growth factor 22 isoform 1 precursorHomo sapiens (human)AbsAC1_uM1.74001.74007.917514.9200AID687022
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (399)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lactate transmembrane transportMonocarboxylate transporter 4Homo sapiens (human)
pyruvate catabolic processMonocarboxylate transporter 4Homo sapiens (human)
pyruvate transmembrane transportMonocarboxylate transporter 4Homo sapiens (human)
monocarboxylic acid transportMonocarboxylate transporter 4Homo sapiens (human)
cell surface receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
MAPK cascadeEpidermal growth factor receptorHomo sapiens (human)
ossificationEpidermal growth factor receptorHomo sapiens (human)
embryonic placenta developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationEpidermal growth factor receptorHomo sapiens (human)
hair follicle developmentEpidermal growth factor receptorHomo sapiens (human)
translationEpidermal growth factor receptorHomo sapiens (human)
signal transductionEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
activation of phospholipase C activityEpidermal growth factor receptorHomo sapiens (human)
salivary gland morphogenesisEpidermal growth factor receptorHomo sapiens (human)
midgut developmentEpidermal growth factor receptorHomo sapiens (human)
learning or memoryEpidermal growth factor receptorHomo sapiens (human)
circadian rhythmEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
diterpenoid metabolic processEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
cerebral cortex cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell growthEpidermal growth factor receptorHomo sapiens (human)
lung developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of superoxide anion generationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
response to cobalaminEpidermal growth factor receptorHomo sapiens (human)
response to hydroxyisoflavoneEpidermal growth factor receptorHomo sapiens (human)
cellular response to reactive oxygen speciesEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
ERBB2-EGFR signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of protein catabolic processEpidermal growth factor receptorHomo sapiens (human)
vasodilationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphorylationEpidermal growth factor receptorHomo sapiens (human)
ovulation cycleEpidermal growth factor receptorHomo sapiens (human)
hydrogen peroxide metabolic processEpidermal growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processEpidermal growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityEpidermal growth factor receptorHomo sapiens (human)
tongue developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA repairEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA replicationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of bone resorptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of vasoconstrictionEpidermal growth factor receptorHomo sapiens (human)
negative regulation of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEpidermal growth factor receptorHomo sapiens (human)
regulation of JNK cascadeEpidermal growth factor receptorHomo sapiens (human)
symbiont entry into host cellEpidermal growth factor receptorHomo sapiens (human)
protein autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
astrocyte activationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEpidermal growth factor receptorHomo sapiens (human)
digestive tract morphogenesisEpidermal growth factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationEpidermal growth factor receptorHomo sapiens (human)
neuron projection morphogenesisEpidermal growth factor receptorHomo sapiens (human)
epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
protein insertion into membraneEpidermal growth factor receptorHomo sapiens (human)
response to calcium ionEpidermal growth factor receptorHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicEpidermal growth factor receptorHomo sapiens (human)
positive regulation of glial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
morphogenesis of an epithelial foldEpidermal growth factor receptorHomo sapiens (human)
eyelid development in camera-type eyeEpidermal growth factor receptorHomo sapiens (human)
response to UV-AEpidermal growth factor receptorHomo sapiens (human)
positive regulation of mucus secretionEpidermal growth factor receptorHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
cellular response to amino acid stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to mechanical stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to cadmium ionEpidermal growth factor receptorHomo sapiens (human)
cellular response to epidermal growth factor stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to estradiol stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to xenobiotic stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to dexamethasone stimulusEpidermal growth factor receptorHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
liver regenerationEpidermal growth factor receptorHomo sapiens (human)
cell-cell adhesionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein kinase C activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of prolactin secretionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of miRNA transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein localization to plasma membraneEpidermal growth factor receptorHomo sapiens (human)
negative regulation of cardiocyte differentiationEpidermal growth factor receptorHomo sapiens (human)
neurogenesisEpidermal growth factor receptorHomo sapiens (human)
multicellular organism developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of kinase activityEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
digestionChymotrypsinogen ABos taurus (cattle)
signal transductionTransthyretinHomo sapiens (human)
purine nucleobase metabolic processTransthyretinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
antral ovarian follicle growthEstrogen receptorHomo sapiens (human)
epithelial cell developmentEstrogen receptorHomo sapiens (human)
chromatin remodelingEstrogen receptorHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
signal transductionEstrogen receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEstrogen receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEstrogen receptorHomo sapiens (human)
androgen metabolic processEstrogen receptorHomo sapiens (human)
male gonad developmentEstrogen receptorHomo sapiens (human)
negative regulation of gene expressionEstrogen receptorHomo sapiens (human)
positive regulation of phospholipase C activityEstrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptorHomo sapiens (human)
response to estradiolEstrogen receptorHomo sapiens (human)
regulation of toll-like receptor signaling pathwayEstrogen receptorHomo sapiens (human)
negative regulation of smooth muscle cell apoptotic processEstrogen receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionEstrogen receptorHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
response to estrogenEstrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
fibroblast proliferationEstrogen receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEstrogen receptorHomo sapiens (human)
stem cell differentiationEstrogen receptorHomo sapiens (human)
regulation of inflammatory responseEstrogen receptorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
RNA polymerase II preinitiation complex assemblyEstrogen receptorHomo sapiens (human)
uterus developmentEstrogen receptorHomo sapiens (human)
vagina developmentEstrogen receptorHomo sapiens (human)
prostate epithelial cord elongationEstrogen receptorHomo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisEstrogen receptorHomo sapiens (human)
regulation of branching involved in prostate gland morphogenesisEstrogen receptorHomo sapiens (human)
mammary gland branching involved in pregnancyEstrogen receptorHomo sapiens (human)
mammary gland alveolus developmentEstrogen receptorHomo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongationEstrogen receptorHomo sapiens (human)
protein localization to chromatinEstrogen receptorHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptorHomo sapiens (human)
negative regulation of miRNA transcriptionEstrogen receptorHomo sapiens (human)
regulation of epithelial cell apoptotic processEstrogen receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptorHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
central nervous system developmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to hypoxiaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female pregnancySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
long-chain fatty acid import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
L-ascorbic acid metabolic processSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cerebral cortex developmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular response to glucose starvationSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
xenobiotic transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
photoreceptor cell maintenanceSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein-containing complex assemblySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular response to mechanical stimulusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular hyperosmotic responseSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to Thyroglobulin triiodothyronineSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose importSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to insulinSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
dehydroascorbic acid transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
chloride transmembrane transportSodium/glucose cotransporter 1Homo sapiens (human)
glucose transmembrane transportSodium/glucose cotransporter 1Homo sapiens (human)
alpha-glucoside transportSodium/glucose cotransporter 1Homo sapiens (human)
intestinal D-glucose absorptionSodium/glucose cotransporter 1Homo sapiens (human)
response to inorganic substanceSodium/glucose cotransporter 1Homo sapiens (human)
pentose transmembrane transportSodium/glucose cotransporter 1Homo sapiens (human)
fucose transmembrane transportSodium/glucose cotransporter 1Homo sapiens (human)
galactose transmembrane transportSodium/glucose cotransporter 1Homo sapiens (human)
myo-inositol transportSodium/glucose cotransporter 1Homo sapiens (human)
transepithelial water transportSodium/glucose cotransporter 1Homo sapiens (human)
renal glucose absorptionSodium/glucose cotransporter 1Homo sapiens (human)
glucose import across plasma membraneSodium/glucose cotransporter 1Homo sapiens (human)
sodium ion import across plasma membraneSodium/glucose cotransporter 1Homo sapiens (human)
intestinal hexose absorptionSodium/glucose cotransporter 1Homo sapiens (human)
transport across blood-brain barrierSodium/glucose cotransporter 1Homo sapiens (human)
glucose transmembrane transportSodium/glucose cotransporter 1Homo sapiens (human)
sodium ion transportSodium/glucose cotransporter 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to lipopolysaccharideNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
apoptotic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
inflammatory responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
JNK cascadeNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of gene expressionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of lipid storageNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of calcidiol 1-monooxygenase activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of vitamin D biosynthetic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of cholesterol transportNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of interleukin-12 productionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
response to muscle stretchNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
non-canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of apoptotic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of inflammatory responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
B cell receptor signaling pathwayNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of protein metabolic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
mammary gland involutionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription initiation by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to mechanical stimulusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to nicotineNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-1Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-6Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to tumor necrosis factorNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to dsRNANuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-17Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to virusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
antibacterial innate immune responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of hyaluronan biosynthetic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to angiotensinNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of miRNA metabolic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to stressNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
innate immune responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
response to cytokineNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
alpha-glucoside transportSodium/glucose cotransporter 2Homo sapiens (human)
carbohydrate metabolic processSodium/glucose cotransporter 2Homo sapiens (human)
hexose transmembrane transportSodium/glucose cotransporter 2Homo sapiens (human)
renal glucose absorptionSodium/glucose cotransporter 2Homo sapiens (human)
glucose import across plasma membraneSodium/glucose cotransporter 2Homo sapiens (human)
sodium ion import across plasma membraneSodium/glucose cotransporter 2Homo sapiens (human)
sodium ion transportSodium/glucose cotransporter 2Homo sapiens (human)
follicular dendritic cell differentiationNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
germinal center formationNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
extracellular matrix organizationNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
response to lipopolysaccharideNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
rhythmic processNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
spleen developmentNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cellular response to stressNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
innate immune responseNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
non-canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
response to cytokineNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
inflammatory responseNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
positive regulation of interleukin-1 beta productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
positive regulation of amyloid-beta formationTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
liver developmentTranscription factor p65Homo sapiens (human)
hair follicle developmentTranscription factor p65Homo sapiens (human)
defense response to tumor cellTranscription factor p65Homo sapiens (human)
response to ischemiaTranscription factor p65Homo sapiens (human)
acetaldehyde metabolic processTranscription factor p65Homo sapiens (human)
chromatin organizationTranscription factor p65Homo sapiens (human)
DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
inflammatory responseTranscription factor p65Homo sapiens (human)
cellular defense responseTranscription factor p65Homo sapiens (human)
neuropeptide signaling pathwayTranscription factor p65Homo sapiens (human)
canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of cell population proliferationTranscription factor p65Homo sapiens (human)
response to xenobiotic stimulusTranscription factor p65Homo sapiens (human)
animal organ morphogenesisTranscription factor p65Homo sapiens (human)
response to UV-BTranscription factor p65Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionTranscription factor p65Homo sapiens (human)
positive regulation of gene expressionTranscription factor p65Homo sapiens (human)
positive regulation of Schwann cell differentiationTranscription factor p65Homo sapiens (human)
negative regulation of angiogenesisTranscription factor p65Homo sapiens (human)
cytokine-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
protein catabolic processTranscription factor p65Homo sapiens (human)
response to muramyl dipeptideTranscription factor p65Homo sapiens (human)
response to progesteroneTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-12 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
response to insulinTranscription factor p65Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein sumoylationTranscription factor p65Homo sapiens (human)
response to cobalaminTranscription factor p65Homo sapiens (human)
toll-like receptor 4 signaling pathwayTranscription factor p65Homo sapiens (human)
intracellular signal transductionTranscription factor p65Homo sapiens (human)
cellular response to hepatocyte growth factor stimulusTranscription factor p65Homo sapiens (human)
response to muscle stretchTranscription factor p65Homo sapiens (human)
non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
vascular endothelial growth factor signaling pathwayTranscription factor p65Homo sapiens (human)
prolactin signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein catabolic processTranscription factor p65Homo sapiens (human)
negative regulation of apoptotic processTranscription factor p65Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
response to amino acidTranscription factor p65Homo sapiens (human)
negative regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTranscription factor p65Homo sapiens (human)
regulation of inflammatory responseTranscription factor p65Homo sapiens (human)
positive regulation of T cell receptor signaling pathwayTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
response to cAMPTranscription factor p65Homo sapiens (human)
defense response to virusTranscription factor p65Homo sapiens (human)
cellular response to hydrogen peroxideTranscription factor p65Homo sapiens (human)
interleukin-1-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to lipopolysaccharideTranscription factor p65Homo sapiens (human)
cellular response to lipoteichoic acidTranscription factor p65Homo sapiens (human)
cellular response to peptidoglycanTranscription factor p65Homo sapiens (human)
cellular response to nicotineTranscription factor p65Homo sapiens (human)
cellular response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to interleukin-6Transcription factor p65Homo sapiens (human)
cellular response to tumor necrosis factorTranscription factor p65Homo sapiens (human)
postsynapse to nucleus signaling pathwayTranscription factor p65Homo sapiens (human)
antiviral innate immune responseTranscription factor p65Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
negative regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
cellular response to angiotensinTranscription factor p65Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellTranscription factor p65Homo sapiens (human)
positive regulation of miRNA metabolic processTranscription factor p65Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayTranscription factor p65Homo sapiens (human)
cellular response to stressTranscription factor p65Homo sapiens (human)
response to cytokineTranscription factor p65Homo sapiens (human)
innate immune responseTranscription factor p65Homo sapiens (human)
sodium ion transportSodium/hydrogen exchanger 9B2Homo sapiens (human)
lithium ion transportSodium/hydrogen exchanger 9B2Homo sapiens (human)
flagellated sperm motilitySodium/hydrogen exchanger 9B2Homo sapiens (human)
monoatomic ion transmembrane transportSodium/hydrogen exchanger 9B2Homo sapiens (human)
sodium ion transmembrane transportSodium/hydrogen exchanger 9B2Homo sapiens (human)
sodium ion homeostasisSodium/hydrogen exchanger 9B2Homo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusSodium/hydrogen exchanger 9B2Homo sapiens (human)
clathrin-dependent endocytosisSodium/hydrogen exchanger 9B2Homo sapiens (human)
proton transmembrane transportSodium/hydrogen exchanger 9B2Homo sapiens (human)
positive regulation of osteoclast developmentSodium/hydrogen exchanger 9B2Homo sapiens (human)
inorganic cation transmembrane transportSodium/hydrogen exchanger 9B2Homo sapiens (human)
xenobiotic metabolic processSolute carrier family 28 member 3Homo sapiens (human)
xenobiotic transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
pyrimidine nucleobase transportSolute carrier family 28 member 3Homo sapiens (human)
uridine transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
sodium ion transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
pyrimidine-containing compound transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
nucleoside transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
purine nucleobase transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
pyrimidine nucleoside transportSolute carrier family 28 member 3Homo sapiens (human)
purine nucleoside transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (112)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
RNA bindingMonocarboxylate transporter 4Homo sapiens (human)
protein bindingMonocarboxylate transporter 4Homo sapiens (human)
monocarboxylic acid transmembrane transporter activityMonocarboxylate transporter 4Homo sapiens (human)
lactate:proton symporter activityMonocarboxylate transporter 4Homo sapiens (human)
pyruvate transmembrane transporter activityMonocarboxylate transporter 4Homo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
virus receptor activityEpidermal growth factor receptorHomo sapiens (human)
chromatin bindingEpidermal growth factor receptorHomo sapiens (human)
double-stranded DNA bindingEpidermal growth factor receptorHomo sapiens (human)
MAP kinase kinase kinase activityEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane signaling receptor activityEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
integrin bindingEpidermal growth factor receptorHomo sapiens (human)
protein bindingEpidermal growth factor receptorHomo sapiens (human)
calmodulin bindingEpidermal growth factor receptorHomo sapiens (human)
ATP bindingEpidermal growth factor receptorHomo sapiens (human)
enzyme bindingEpidermal growth factor receptorHomo sapiens (human)
kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein phosphatase bindingEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
ubiquitin protein ligase bindingEpidermal growth factor receptorHomo sapiens (human)
identical protein bindingEpidermal growth factor receptorHomo sapiens (human)
cadherin bindingEpidermal growth factor receptorHomo sapiens (human)
actin filament bindingEpidermal growth factor receptorHomo sapiens (human)
ATPase bindingEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor bindingEpidermal growth factor receptorHomo sapiens (human)
protein bindingChymotrypsinogen ABos taurus (cattle)
serpin family protein bindingChymotrypsinogen ABos taurus (cattle)
hormone activityTransthyretinHomo sapiens (human)
protein bindingTransthyretinHomo sapiens (human)
identical protein bindingTransthyretinHomo sapiens (human)
thyroid hormone bindingTransthyretinHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
TFIIB-class transcription factor bindingEstrogen receptorHomo sapiens (human)
transcription coregulator bindingEstrogen receptorHomo sapiens (human)
transcription corepressor bindingEstrogen receptorHomo sapiens (human)
transcription coactivator bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
chromatin bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
nuclear receptor activityEstrogen receptorHomo sapiens (human)
steroid bindingEstrogen receptorHomo sapiens (human)
protein bindingEstrogen receptorHomo sapiens (human)
calmodulin bindingEstrogen receptorHomo sapiens (human)
beta-catenin bindingEstrogen receptorHomo sapiens (human)
zinc ion bindingEstrogen receptorHomo sapiens (human)
TBP-class protein bindingEstrogen receptorHomo sapiens (human)
enzyme bindingEstrogen receptorHomo sapiens (human)
protein kinase bindingEstrogen receptorHomo sapiens (human)
nitric-oxide synthase regulator activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor bindingEstrogen receptorHomo sapiens (human)
estrogen response element bindingEstrogen receptorHomo sapiens (human)
identical protein bindingEstrogen receptorHomo sapiens (human)
ATPase bindingEstrogen receptorHomo sapiens (human)
14-3-3 protein bindingEstrogen receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen receptorHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
long-chain fatty acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
kinase bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
dehydroascorbic acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
identical protein bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
D-glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
galactose transmembrane transporter activitySodium/glucose cotransporter 1Homo sapiens (human)
glucose transmembrane transporter activitySodium/glucose cotransporter 1Homo sapiens (human)
myo-inositol:sodium symporter activitySodium/glucose cotransporter 1Homo sapiens (human)
water transmembrane transporter activitySodium/glucose cotransporter 1Homo sapiens (human)
glucose:sodium symporter activitySodium/glucose cotransporter 1Homo sapiens (human)
protein bindingSodium/glucose cotransporter 1Homo sapiens (human)
pentose transmembrane transporter activitySodium/glucose cotransporter 1Homo sapiens (human)
fucose transmembrane transporter activitySodium/glucose cotransporter 1Homo sapiens (human)
alpha-glucoside transmembrane transporter activitySodium/glucose cotransporter 1Homo sapiens (human)
galactose:sodium symporter activitySodium/glucose cotransporter 1Homo sapiens (human)
D-glucose transmembrane transporter activitySodium/glucose cotransporter 1Homo sapiens (human)
transcription cis-regulatory region bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
chromatin bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription factor activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription coregulator activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
protein bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
identical protein bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
actinin bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
low-affinity glucose:sodium symporter activitySodium/glucose cotransporter 2Homo sapiens (human)
glucose:sodium symporter activitySodium/glucose cotransporter 2Homo sapiens (human)
protein bindingSodium/glucose cotransporter 2Homo sapiens (human)
alpha-glucoside transmembrane transporter activitySodium/glucose cotransporter 2Homo sapiens (human)
D-glucose transmembrane transporter activitySodium/glucose cotransporter 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
DNA-binding transcription factor activityNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
protein bindingNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
transcription cis-regulatory region bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
transcription coactivator bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA bindingTranscription factor p65Homo sapiens (human)
chromatin bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activityTranscription factor p65Homo sapiens (human)
protein bindingTranscription factor p65Homo sapiens (human)
enzyme bindingTranscription factor p65Homo sapiens (human)
protein kinase bindingTranscription factor p65Homo sapiens (human)
chromatin DNA bindingTranscription factor p65Homo sapiens (human)
ubiquitin protein ligase bindingTranscription factor p65Homo sapiens (human)
peptide bindingTranscription factor p65Homo sapiens (human)
phosphate ion bindingTranscription factor p65Homo sapiens (human)
identical protein bindingTranscription factor p65Homo sapiens (human)
protein homodimerization activityTranscription factor p65Homo sapiens (human)
actinin bindingTranscription factor p65Homo sapiens (human)
histone deacetylase bindingTranscription factor p65Homo sapiens (human)
NF-kappaB bindingTranscription factor p65Homo sapiens (human)
ankyrin repeat bindingTranscription factor p65Homo sapiens (human)
general transcription initiation factor bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor bindingTranscription factor p65Homo sapiens (human)
protein bindingSodium/hydrogen exchanger 9B2Homo sapiens (human)
lithium:proton antiporter activitySodium/hydrogen exchanger 9B2Homo sapiens (human)
sodium:proton antiporter activitySodium/hydrogen exchanger 9B2Homo sapiens (human)
identical protein bindingSodium/hydrogen exchanger 9B2Homo sapiens (human)
purine nucleobase transmembrane transporter activitySolute carrier family 28 member 3Homo sapiens (human)
nucleoside:sodium symporter activitySolute carrier family 28 member 3Homo sapiens (human)
protein bindingSolute carrier family 28 member 3Homo sapiens (human)
uridine transmembrane transporter activitySolute carrier family 28 member 3Homo sapiens (human)
purine-specific nucleoside:sodium symporter activitySolute carrier family 28 member 3Homo sapiens (human)
pyrimidine- and adenosine-specific:sodium symporter activitySolute carrier family 28 member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (80)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
membraneMonocarboxylate transporter 4Homo sapiens (human)
basolateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
apical plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
lateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
nuclear membraneMonocarboxylate transporter 4Homo sapiens (human)
plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
basolateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
ruffle membraneEpidermal growth factor receptorHomo sapiens (human)
Golgi membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceEpidermal growth factor receptorHomo sapiens (human)
nucleusEpidermal growth factor receptorHomo sapiens (human)
cytoplasmEpidermal growth factor receptorHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
endoplasmic reticulum membraneEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
focal adhesionEpidermal growth factor receptorHomo sapiens (human)
cell surfaceEpidermal growth factor receptorHomo sapiens (human)
endosome membraneEpidermal growth factor receptorHomo sapiens (human)
membraneEpidermal growth factor receptorHomo sapiens (human)
basolateral plasma membraneEpidermal growth factor receptorHomo sapiens (human)
apical plasma membraneEpidermal growth factor receptorHomo sapiens (human)
cell junctionEpidermal growth factor receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneEpidermal growth factor receptorHomo sapiens (human)
early endosome membraneEpidermal growth factor receptorHomo sapiens (human)
nuclear membraneEpidermal growth factor receptorHomo sapiens (human)
membrane raftEpidermal growth factor receptorHomo sapiens (human)
perinuclear region of cytoplasmEpidermal growth factor receptorHomo sapiens (human)
multivesicular body, internal vesicle lumenEpidermal growth factor receptorHomo sapiens (human)
intracellular vesicleEpidermal growth factor receptorHomo sapiens (human)
protein-containing complexEpidermal growth factor receptorHomo sapiens (human)
receptor complexEpidermal growth factor receptorHomo sapiens (human)
Shc-EGFR complexEpidermal growth factor receptorHomo sapiens (human)
basal plasma membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular regionChymotrypsinogen ABos taurus (cattle)
serine protease inhibitor complexChymotrypsinogen ABos taurus (cattle)
extracellular regionTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
azurophil granule lumenTransthyretinHomo sapiens (human)
extracellular exosomeTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleoplasmEstrogen receptorHomo sapiens (human)
transcription regulator complexEstrogen receptorHomo sapiens (human)
cytoplasmEstrogen receptorHomo sapiens (human)
Golgi apparatusEstrogen receptorHomo sapiens (human)
cytosolEstrogen receptorHomo sapiens (human)
plasma membraneEstrogen receptorHomo sapiens (human)
membraneEstrogen receptorHomo sapiens (human)
chromatinEstrogen receptorHomo sapiens (human)
euchromatinEstrogen receptorHomo sapiens (human)
protein-containing complexEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
Golgi membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female germ cell nucleusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
photoreceptor inner segmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female pronucleusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cytosolSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
caveolaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
intercalated discSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
Z discSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
midbodySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cortical actin cytoskeletonSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
sarcolemmaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
melanosomeSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
extracellular exosomeSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
blood microparticleSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
presynapseSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transporter complexSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
early endosomeSodium/glucose cotransporter 1Homo sapiens (human)
plasma membraneSodium/glucose cotransporter 1Homo sapiens (human)
apical plasma membraneSodium/glucose cotransporter 1Homo sapiens (human)
brush border membraneSodium/glucose cotransporter 1Homo sapiens (human)
intracellular organelleSodium/glucose cotransporter 1Homo sapiens (human)
perinuclear region of cytoplasmSodium/glucose cotransporter 1Homo sapiens (human)
extracellular exosomeSodium/glucose cotransporter 1Homo sapiens (human)
intracellular vesicleSodium/glucose cotransporter 1Homo sapiens (human)
plasma membraneSodium/glucose cotransporter 1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
extracellular regionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
mitochondrionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytosolNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
secretory granule lumenNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
specific granule lumenNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
chromatinNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription regulator complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
I-kappaB/NF-kappaB complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
NF-kappaB p50/p65 complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
plasma membraneSodium/glucose cotransporter 2Homo sapiens (human)
membraneSodium/glucose cotransporter 2Homo sapiens (human)
apical plasma membraneSodium/glucose cotransporter 2Homo sapiens (human)
extracellular exosomeSodium/glucose cotransporter 2Homo sapiens (human)
plasma membraneSodium/glucose cotransporter 2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleusNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
nucleoplasmNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cytosolNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
chromatinNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
Bcl3/NF-kappaB2 complexNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
nucleusNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
nucleolusTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
glutamatergic synapseTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
nucleoplasmTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
cytosolTranscription factor p65Homo sapiens (human)
NF-kappaB p50/p65 complexTranscription factor p65Homo sapiens (human)
NF-kappaB complexTranscription factor p65Homo sapiens (human)
chromatinTranscription factor p65Homo sapiens (human)
transcription regulator complexTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
mitochondrial inner membraneSodium/hydrogen exchanger 9B2Homo sapiens (human)
plasma membraneSodium/hydrogen exchanger 9B2Homo sapiens (human)
basolateral plasma membraneSodium/hydrogen exchanger 9B2Homo sapiens (human)
apical plasma membraneSodium/hydrogen exchanger 9B2Homo sapiens (human)
synaptic vesicle membraneSodium/hydrogen exchanger 9B2Homo sapiens (human)
mitochondrial membraneSodium/hydrogen exchanger 9B2Homo sapiens (human)
recycling endosomeSodium/hydrogen exchanger 9B2Homo sapiens (human)
recycling endosome membraneSodium/hydrogen exchanger 9B2Homo sapiens (human)
sperm principal pieceSodium/hydrogen exchanger 9B2Homo sapiens (human)
endoplasmic reticulum membraneSolute carrier family 28 member 3Homo sapiens (human)
plasma membraneSolute carrier family 28 member 3Homo sapiens (human)
brush border membraneSolute carrier family 28 member 3Homo sapiens (human)
plasma membraneSolute carrier family 28 member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (198)

Assay IDTitleYearJournalArticle
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1232398Inhibition of diphenolase activity of mushroom tyrosinase using L-dopa as substrate at 0.2 mM by spectrophotometric assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Identification of p-hydroxybenzyl alcohol, tyrosol, phloretin and its derivate phloridzin as tyrosinase substrates.
AID1436780Inhibition of human SGLT1 expressed in HEK293 cells assessed as reduction in 2-deoxyglucose uptake at 100 uM pretreated for 10 mins followed by 2-deoxyglucose addition in presence of sodium buffer measured after 1 hr by resazurin dye based fluorescence as2017Journal of medicinal chemistry, 01-26, Volume: 60, Issue:2
Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1510605Inhibition of alpha-chymotrypsin in bovine pancreas using SPpNA as substrate pretreated with enzyme for 30 mins followed by substrate addition and measured for 12 mins by spectrophotometric analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors.
AID1058214Binding affinity to human estrogen receptor assessed as decrease in estradiol-dependent beta-galactosidase activity2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells.
AID1893805Inhibition of cellular uptake of fluorescent glucose 2-NBDG in human A2780 cells at 50 uM incubated for 20 mins by flow cytometry2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
Aroylhydrazone Glycoconjugate Prochelators Exploit Glucose Transporter 1 (GLUT1) to Target Iron in Cancer Cells.
AID1232404Activity at mushroom tyrosinase by spectrophotometric assay in presence of hydrogen peroxide2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Identification of p-hydroxybenzyl alcohol, tyrosol, phloretin and its derivate phloridzin as tyrosinase substrates.
AID1232397Inhibition of diphenolase activity of mushroom tyrosinase using L-dopa as substrate at 0.1 mM by spectrophotometric assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Identification of p-hydroxybenzyl alcohol, tyrosol, phloretin and its derivate phloridzin as tyrosinase substrates.
AID1232391Inhibition of monophenolase activity of mushroom tyrosinase using L-tyrosine as substrate at 0.2 mM by spectrophotometric assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Identification of p-hydroxybenzyl alcohol, tyrosol, phloretin and its derivate phloridzin as tyrosinase substrates.
AID1510608Inhibition of Enterobacter cloacae beta-lactamase treated with enzyme for 10 mins following enzyme incubation with 0.7 to 2.1 M DMSO for 5 mins followed by nitrocefin substrate challenge and measured for 5 mins by DMSO perturbation assay2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors.
AID696433Inhibition of bovine kidney LMW-PTPase at 400 uM using pNPP substrate2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Low molecular weight phosphotyrosine protein phosphatases as emerging targets for the design of novel therapeutic agents.
AID1286193Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay2016Journal of natural products, Jan-22, Volume: 79, Issue:1
Cytotoxic Evaluation against Breast Cancer Cells of Isoliquiritigenin Analogues from Spatholobus suberectus and Their Synthetic Derivatives.
AID1232400Activity at mushroom tyrosinase assessed as decrease in absorbance at 475 nm using L-dopa as substrate by spectrophotometric assay in presence of sodium periodate2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Identification of p-hydroxybenzyl alcohol, tyrosol, phloretin and its derivate phloridzin as tyrosinase substrates.
AID1510607Inhibition of alpha-chymotrypsin in bovine pancreas using SPpNA as substrate pretreated with enzyme for 30 mins followed by substrate addition and measured for 12 mins in presence of Triton X-100 by spectrophotometric analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors.
AID293299Antioxidant activity in BALB/c mouse BM cells assessed as inhibition of ROS production2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems.
AID456319ABTS radical scavenging activity assessed as vitamin C equivalent antioxidant capacity2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID378515Inhibition of LPS-induced mouse B cells proliferation assessed as [3H]TdR incorporation at 1 uM by MTT assay2005Journal of natural products, Mar, Volume: 68, Issue:3
Dihydrochalcones from the leaves of Pieris japonica.
AID1510606Inhibition of alpha-chymotrypsin in bovine pancreas at 300 uM using SPpNA as substrate pretreated with enzyme for 30 mins followed by substrate addition and measured for 12 mins by spectrophotometric analysis relative to control2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors.
AID1264945Induction of osteogenic differentiation in human MSC assessed as increase in ALP activity at 1 uM using p-NPP as substrate after 9 days by colorimetric method relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID427049Binding affinity to Escherichia coli KAS3 expressed in Escherichia coli BL21 (DE3) by NMR analysis2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Antimicrobial natural products as beta-ketoacyl-acyl carrier protein synthase III inhibitors.
AID640008Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 14 after 24 hrs by broth microdilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus.
AID640012Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 10 after 24 hrs by broth microdilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus.
AID1464929Inhibition of porcine pancreatic lipase using p-nitrophenyl butyrate as substrate pretreated for 15 mins followed by substrate addition measured after 15 mins by spectrophotometric method2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Plasma-induced dimerization of phloridzin as a new class of anti-adipogenic agents.
AID388001Antibacterial activity against Bacillus cereus ATCC 11778 after 24 hrs by microdilution broth method2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Structure-activity relationship of antibacterial chalcones.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1058218Inhibition of GLUT1 in human H1299 cells assessed as inhibition of 2-deoxy-D-[3H]-glucose uptake incubated for 15 mins prior to 2-deoxy-D-[3H]-glucose addition measured after 30 mins by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells.
AID456318DPPH radical scavenging activity assessed as trolox equivalent antioxidant capacity2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID640015Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 7 after 24 hrs by broth microdilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus.
AID388004Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by microdilution broth method2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Structure-activity relationship of antibacterial chalcones.
AID1264957Cytotoxicity against human MSC assessed as cell viability at 5 uM treated for 6 days measured on day 7 by alamar blue assay (Rvb = 96 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID293298Antioxidant activity assessed as inhibition of superoxide production by xanthine/xanthine oxidase method2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems.
AID381258Cytotoxicity against human 9KB cells relative to control
AID681182TP_TRANSPORTER: increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 uM, Phloretin: 50 uM) in BCRP-expressing NCI-H460 cells2004Molecular pharmacology, May, Volume: 65, Issue:5
Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.
AID1232389Inhibition of monophenolase activity of mushroom tyrosinase using L-tyrosine as substrate at 0.05 mM by spectrophotometric assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Identification of p-hydroxybenzyl alcohol, tyrosol, phloretin and its derivate phloridzin as tyrosinase substrates.
AID1264956Cytotoxicity against human MSC assessed as cell viability at 1 uM treated for 6 days measured on day 7 by alamar blue assay (Rvb = 96 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1058216Cytotoxicity against human H1299 cells assessed as growth inhibition after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells.
AID1510617Inhibition of Enterobacter cloacae beta-lactamase incubated for 10 mins followed by nitrocefin substrate challenge and measured for 5 mins in presence of 1 mM DTT by spectrophotometric analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors.
AID1264954Cytotoxicity against human MSC assessed as cell viability at 5 uM treated for 3 days measured on day 4 by alamar blue assay (Rvb = 97 to 100%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1286194Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay2016Journal of natural products, Jan-22, Volume: 79, Issue:1
Cytotoxic Evaluation against Breast Cancer Cells of Isoliquiritigenin Analogues from Spatholobus suberectus and Their Synthetic Derivatives.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1436776Inhibition of human SGLT1 expressed in HEK293 cells assessed as reduction in 2-deoxyglucose uptake pretreated for 10 mins followed by 2-deoxyglucose addition in presence of sodium buffer measured after 1 hr by resazurin dye based fluorescence assay2017Journal of medicinal chemistry, 01-26, Volume: 60, Issue:2
Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation.
AID1264958Cytotoxicity against human MSC assessed as cell viability at 10 uM treated for 6 days measured on day 7 by alamar blue assay (Rvb = 96 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID293297Antioxidant activity assessed as DPPH radical scavenging activity after 20 min2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems.
AID1264951Cytotoxicity against human MSC assessed as cell viability at 5 uM measured on day 1 by alamar blue assay (Rvb = 97 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1264955Cytotoxicity against human MSC assessed as cell viability at 10 uM treated for 3 days measured on day 4 by alamar blue assay (Rvb = 97 to 100%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1264953Cytotoxicity against human MSC assessed as cell viability at 1 uM treated for 3 days measured on day 4 by alamar blue assay (Rvb = 97 to 100%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1420939Antibacterial activity against Escherichia coli ATCC 10536 by agar diffusion method2018European journal of medicinal chemistry, Oct-05, Volume: 158Antibacterial and antioxidant activities for natural and synthetic dual-active compounds.
AID388003Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by microdilution broth method2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Structure-activity relationship of antibacterial chalcones.
AID388002Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by microdilution broth method2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Structure-activity relationship of antibacterial chalcones.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID678792TP_TRANSPORTER: inhibition of L-Lactate uptake (L-Lactate:30mM) in Xenopus laevis oocytes2000The Journal of physiology, Dec-01, Volume: 529 Pt 2Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle.
AID1436783Inhibition of GLUT in HEK293 cells assessed as reduction in 2-deoxyglucose uptake at 100 uM pretreated for 10 mins followed by 2-deoxyglucose addition in presence of choline buffer measured after 1 hr by resazurin dye based fluorescence assay2017Journal of medicinal chemistry, 01-26, Volume: 60, Issue:2
Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation.
AID205450Binding affinity against Sodium/glucose co-transporter of isolated renal brush border membranes.2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Probing the conformation of the sugar transport inhibitor phlorizin by 2D-NMR, molecular dynamics studies, and pharmacophore analysis.
AID640011Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 11 after 24 hrs by broth microdilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus.
AID640020Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 2 after 24 hrs by broth microdilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus.
AID378512Inhibition of concanavalin A-induced mouse T cells proliferation assessed as [3H]TdR incorporation at 1 uM by MTT assay2005Journal of natural products, Mar, Volume: 68, Issue:3
Dihydrochalcones from the leaves of Pieris japonica.
AID678839TP_TRANSPORTER: cell accumulation of daunomycin in MDA435/LCC6MDR1 cells2003The Journal of pharmacology and experimental therapeutics, Mar, Volume: 304, Issue:3
Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport.
AID640017Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 5 after 24 hrs by broth microdilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus.
AID378511Inhibition of concanavalin A-induced mouse T cells proliferation assessed as [3H]TdR incorporation at 0.1 uM by MTT assay2005Journal of natural products, Mar, Volume: 68, Issue:3
Dihydrochalcones from the leaves of Pieris japonica.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID681123TP_TRANSPORTER: inhibition of lactate uptake in Xenopus laevis oocytes1999The Biochemical journal, Aug-01, Volume: 341 ( Pt 3)Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes.
AID681133TP_TRANSPORTER: inhibition of lactate uptake in Xenopus laevis oocytes1999The Biochemical journal, Aug-01, Volume: 341 ( Pt 3)Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes.
AID1510613Inhibition of Enterobacter cloacae beta-lactamase incubated for 10 mins followed by nitrocefin substrate challenge and measured for 5 mins in presence of 0.1 to 0.5 M DMA by spectrophotometric analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors.
AID640016Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 6 after 24 hrs by broth microdilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus.
AID1705465Stabilization of TTR V30M mutant (unknown origin) assessed as inhibition of protein-mediated amyloid fibril formation2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Transthyretin Amyloidogenesis Inhibitors: From Discovery to Current Developments.
AID427050Antibacterial activity against vancomycin-resistant Enterococcus faecalis clinical isolates after 20 hrs by twofold serial broth dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Antimicrobial natural products as beta-ketoacyl-acyl carrier protein synthase III inhibitors.
AID1264950Cytotoxicity against human MSC assessed as cell viability at 1 uM measured on day 1 by alamar blue assay (Rvb = 97 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1232390Inhibition of monophenolase activity of mushroom tyrosinase using L-tyrosine as substrate at 0.1 mM by spectrophotometric assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Identification of p-hydroxybenzyl alcohol, tyrosol, phloretin and its derivate phloridzin as tyrosinase substrates.
AID310859Inhibition of HIV1 protease at 50 ug/mL2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
A review of anti-infective and anti-inflammatory chalcones.
AID427044Antibacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3114 after 20 hrs by twofold serial broth dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Antimicrobial natural products as beta-ketoacyl-acyl carrier protein synthase III inhibitors.
AID378514Inhibition of LPS-induced mouse B cells proliferation assessed as [3H]TdR incorporation at 0.1 uM by MTT assay2005Journal of natural products, Mar, Volume: 68, Issue:3
Dihydrochalcones from the leaves of Pieris japonica.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID427051Cytotoxicity against human HaCaT cells assessed as cell morphology at 100 uM after 24 hrs by phase contrast microscopy2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Antimicrobial natural products as beta-ketoacyl-acyl carrier protein synthase III inhibitors.
AID332645Inhibition of calf thymus DNA topoisomerase 1 catalytic domain-mediated supercoiled Escherichia coli pUC8 DNA relaxation up to 100 uM after 30 mins by agarose gel electrophoresis1995Journal of natural products, Feb, Volume: 58, Issue:2
Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships.
AID681321TP_TRANSPORTER: increase in Daunomycin intracellular accumulation (Daunomycin: 0.05 uM, Phloretin: 100 uM) in PANC-1 cells2003Journal of pharmaceutical sciences, Feb, Volume: 92, Issue:2
Effect of flavonoids on MRP1-mediated transport in Panc-1 cells.
AID639978Cytotoxicity against african green monkey Vero cells assessed as cell death after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus.
AID381256Cytotoxicity against human 9KB cells assessed as cell survival at 100 ug/ml relative to control
AID1464930Cytotoxicity against mouse 3T3L1 cells up to 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Plasma-induced dimerization of phloridzin as a new class of anti-adipogenic agents.
AID1510614Inhibition of Enterobacter cloacae beta-lactamase incubated for 10 mins followed by nitrocefin substrate challenge and measured for 5 mins in presence of 0.1 to 0.5 M GdnHCl by spectrophotometric analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors.
AID1420938Antibacterial activity against Staphylococcus aureus ATCC 6538 by agar diffusion method2018European journal of medicinal chemistry, Oct-05, Volume: 158Antibacterial and antioxidant activities for natural and synthetic dual-active compounds.
AID681310TP_TRANSPORTER: increase in Vinblastine intracellular accumulation (Vinblastine: 0.05 uM, Phloretin: 100 uM) in PANC-1 cells2003Journal of pharmaceutical sciences, Feb, Volume: 92, Issue:2
Effect of flavonoids on MRP1-mediated transport in Panc-1 cells.
AID456316ABTS radical scavenging activity assessed as trolox equivalent antioxidant capacity2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID639977Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell growth after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus.
AID370698Binding affinity to human recombinant CNT3 expressed in pig PK15NTD cells assessed as [3H]uridine uptake by beta-scintillation counter2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors.
AID640010Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 12 after 24 hrs by broth microdilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus.
AID1436779Inhibition of human SGLT2 expressed in HEK293 cells assessed as reduction in 2-deoxyglucose uptake at 100 uM pretreated for 10 mins followed by 2-deoxyglucose addition in presence of sodium buffer measured after 1 hr by resazurin dye based fluorescence as2017Journal of medicinal chemistry, 01-26, Volume: 60, Issue:2
Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation.
AID640021Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 1 after 24 hrs by broth microdilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus.
AID381257Cytotoxicity against human 9KB cells assessed as cell survival at 10 ug/ml relative to control
AID1436777Inhibition of human SGLT2 expressed in HEK293 cells assessed as reduction in 2-deoxyglucose uptake pretreated for 10 mins followed by 2-deoxyglucose addition in presence of sodium buffer measured after 1 hr by resazurin dye based fluorescence assay2017Journal of medicinal chemistry, 01-26, Volume: 60, Issue:2
Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation.
AID1264952Cytotoxicity against human MSC assessed as cell viability at 10 uM measured on day 1 by alamar blue assay (Rvb = 97 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1510604Inhibition of Enterobacter cloacae beta-lactamase incubated for 10 mins followed by nitrocefin substrate challenge and measured for 5 mins in presence of Triton X-100 by spectrophotometric analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors.
AID640009Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 13 after 24 hrs by broth microdilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus.
AID1142307Inhibition of NF-kappaB transactivation in TNF-alpha-stimulated human K562 cells preincubated for 2 hrs followed by TNF-alpha challenge measured after 6 hrs by dual luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Bis(4-hydroxy-2H-chromen-2-one): synthesis and effects on leukemic cell lines proliferation and NF-κB regulation.
AID640013Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 9 after 24 hrs by broth microdilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus.
AID427048Antibacterial activity against Escherichia coli after 20 hrs by twofold serial broth dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Antimicrobial natural products as beta-ketoacyl-acyl carrier protein synthase III inhibitors.
AID427053Cytotoxicity against human HaCaT cells assessed as cell survival at 100 uM after 24 hrs by MTT assay2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Antimicrobial natural products as beta-ketoacyl-acyl carrier protein synthase III inhibitors.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1264947Induction of osteogenic differentiation in human MSC assessed as increase in ALP activity at 10 uM using p-NPP as substrate after 9 days by colorimetric method relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID681197TP_TRANSPORTER: increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 uM, Phloretin: 50 uM) in BCRP-expressing MCF-7 cells2004Molecular pharmacology, May, Volume: 65, Issue:5
Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.
AID1436774Cytotoxicity in HEK293 cells assessed as cell viability at 100 uM measured after 20 to 24 hrs by Cell-Titer Blue fluorescence assay2017Journal of medicinal chemistry, 01-26, Volume: 60, Issue:2
Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation.
AID1510602Inhibition of Enterobacter cloacae beta-lactamase incubated for 10 mins followed by nitrocefin substrate challenge and measured for 5 mins by spectrophotometric analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors.
AID378668Inhibition of EGFR2006Journal of natural products, Jan, Volume: 69, Issue:1
A common protein fold topology shared by flavonoid biosynthetic enzymes and therapeutic targets.
AID640022Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 after 24 hrs by broth microdilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus.
AID1420940Antioxidant activity assessed as BTH equivalent of DPPH-induced radical scavenging activity2018European journal of medicinal chemistry, Oct-05, Volume: 158Antibacterial and antioxidant activities for natural and synthetic dual-active compounds.
AID640018Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 4 after 24 hrs by broth microdilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus.
AID640023Selectivity index, Ratio of CC50 for african green monkey Vero cells to IC50 for african green monkey Vero cells2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus.
AID332652Inhibition of human DNA topoisomerase 2 catalytic domain-mediated knotted bacteriophage P4Virl dell0 DNA unknotting by agarose gel electrophoresis1995Journal of natural products, Feb, Volume: 58, Issue:2
Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships.
AID640019Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 3 after 24 hrs by broth microdilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus.
AID640014Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 8 after 24 hrs by broth microdilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1264946Induction of osteogenic differentiation in human MSC assessed as increase in ALP activity at 5 uM using p-NPP as substrate after 9 days by colorimetric method relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID378513Inhibition of concanavalin A-induced mouse T cells proliferation assessed as [3H]TdR incorporation at 10 uM by MTT assay2005Journal of natural products, Mar, Volume: 68, Issue:3
Dihydrochalcones from the leaves of Pieris japonica.
AID427046Antibacterial activity against Staphylococcus aureus KCTC 1621 after 20 hrs by twofold serial broth dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Antimicrobial natural products as beta-ketoacyl-acyl carrier protein synthase III inhibitors.
AID427045Antibacterial activity against Enterococcus faecalis KCTC 2011 after 20 hrs by twofold serial broth dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Antimicrobial natural products as beta-ketoacyl-acyl carrier protein synthase III inhibitors.
AID1232396Inhibition of diphenolase activity of mushroom tyrosinase using L-dopa as substrate at 0.05 mM by spectrophotometric assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Identification of p-hydroxybenzyl alcohol, tyrosol, phloretin and its derivate phloridzin as tyrosinase substrates.
AID378516Inhibition of LPS-induced mouse B cells proliferation assessed as [3H]TdR incorporation at 10 uM by MTT assay2005Journal of natural products, Mar, Volume: 68, Issue:3
Dihydrochalcones from the leaves of Pieris japonica.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2007Journal of molecular biology, Jun-08, Volume: 369, Issue:3
Crystal structures of multidrug binding protein TtgR in complex with antibiotics and plant antimicrobials.
AID1345074Human Sodium-dependent vitamin C transporter 1 (SLC23 family of ascorbic acid transporters)1999Nature, May-06, Volume: 399, Issue:6731
A family of mammalian Na+-dependent L-ascorbic acid transporters.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,194)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990511 (42.80)18.7374
1990's166 (13.90)18.2507
2000's200 (16.75)29.6817
2010's223 (18.68)24.3611
2020's94 (7.87)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.62 (24.57)
Research Supply Index7.11 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index149.69 (26.88)
Search Engine Supply Index3.99 (0.95)

This Compound (45.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (0.41%)5.53%
Reviews28 (2.29%)6.00%
Case Studies1 (0.08%)4.05%
Observational0 (0.00%)0.25%
Other1,189 (97.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]